Antidiabetic and antihypertensive effect of dehydrozingerone in model of streptozotocin induced diabetic and nω- nitro-l arginine methyl ester hydrochloride (l-name) hypertensive rats

Diabetic hypertension continues to be the leading health problem around the globe. The goal of this study was to examine the effect of dehydrozingerone (DZ), (4-(4-hydroxy-3-methoxyphenyl)-3-buten-2-one) on type 2 diabetes and hypertension induced in male Wistar rats. Type 2 Diabetes mellitus was induced by a single intraperitoneal injection (40 mg/kg bw) of streptozotocin (STZ) and hypertension was induced by daily oral administration of Nω-Nitro-L-arginine methyl ester (L-NAME) 40 mg/kg bw dissolved in drinking water for 4 weeks. Effects of DZ against diabetic hypertension were assessed by measuring systolic and diastolic blood pressure, and biochemical parameters such as plasma glucose, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltranspeptidase (GGT), in serum and urea, uric acid and creatinine in plasma. Intraperitoneal injection of DZ (50, 100 and 200 mg/kg bw) to diabetic hypertensive induced rats significantly reduced plasma glucose levels and systolic and diastolic blood pressure. The hepatic and renal functional markers are also significantly decreased. Our histopathological examination confirmed the biochemical findings. Among the three doses used, DZ at a dose of 100 mg/kg was effective compared to other two doses. Our results suggested that DZ has the potential to reduce diabetic and hypertension in STZ and L-NAME induced diabetic hypertensive rats.